Opexa Therapeutics, Inc.

Opexa Therapeutics, Inc.

Opexa Therapeutics, Inc. is dedicated to the development of patient-specific cellular therapies for the treatment of autoimmune diseases such as multiple sclerosis (MS). The Company’s lead therapy, Tovaxin®, a personalized cellular immunotherapy treatment, is in late stage clinical development targeting both Secondary Progressive and Relapsing Remitting MS. Tovaxin is derived from T-cells isolated from peripheral blood, expanded ex vivo, and reintroduced into the patients via subcutaneous injections. This process triggers a potent immune response against specific subsets of autoreactive T-cells known to attack myelin and, thereby, reduces the risk of relapse over time.

For more information, please visit the Company’s website at www.opexatherapeutics.com. 

 

 


 

 

 

 

 

 

Source: Opexa Therapeutics, Inc.

Neil Warma
2635 N. Crescent Ridge Drive
The Woodlands Texas 77381
US
(281) 719-3437
(281) 872-8585 fax.
Category: graduate companies | Sub Category: life science